In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was $12.12 for the day, down -0.82% from the previous closing price of $12.22. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 1.19 million shares were traded. AUPH stock price reached its highest trading level at $12.29 during the session, while it also had its lowest trading level at $11.96.
Ratios:
Our analysis of AUPH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.29. For the most recent quarter (mrq), Quick Ratio is recorded 4.63 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.19.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1595350016 and an Enterprise Value of 1362135040. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.34, and their Forward P/E ratio for the next fiscal year is 15.91. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.13 while its Price-to-Book (P/B) ratio in mrq is 4.80. Its current Enterprise Value per Revenue stands at 5.237 whereas that against EBITDA is 16.494.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.31, which has changed by 0.65573776 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $13.54, while it has fallen to a 52-week low of $6.55. The 50-Day Moving Average of the stock is 0.49%, while the 200-Day Moving Average is calculated to be 29.43%.
Shares Statistics:
AUPH traded an average of 1.96M shares per day over the past three months and 1105030 shares per day over the past ten days. A total of 132.67M shares are outstanding, with a floating share count of 118.93M. Insiders hold about 9.65% of the company’s shares, while institutions hold 43.92% stake in the company. Shares short for AUPH as of 1760486400 were 8394164 with a Short Ratio of 4.29, compared to 1757894400 on 8982210. Therefore, it implies a Short% of Shares Outstanding of 8394164 and a Short% of Float of 6.99.
Earnings Estimates
The market rating for Aurinia Pharmaceuticals Inc (AUPH) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.15, with high estimates of $0.22 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.81 and $0.5 for the fiscal current year, implying an average EPS of $0.65. EPS for the following year is $0.76, with 6.0 analysts recommending between $1.22 and $0.57.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $71.1M to a low estimate of $65.03M. As of. The current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $67.77MFor the next quarter, 7 analysts are estimating revenue of $70.27M. There is a high estimate of $72.6M for the next quarter, whereas the lowest estimate is $66.5M.
A total of 7 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $276.2M, while the lowest revenue estimate was $265M, resulting in an average revenue estimate of $270.48M. In the same quarter a year ago, actual revenue was $235.13MBased on 7 analysts’ estimates, the company’s revenue will be $309.2M in the next fiscal year. The high estimate is $356.92M and the low estimate is $284.45M.
